111 results on '"Cappannoli, Luigi"'
Search Results
2. Thin-cap fibroatheroma: The trigger of acute coronary syndromes. Pathophysiological and prognostic importance of in-vivo detection.
3. Prevalence and characteristics of myocardial injury during COVID-19 pandemic: A new role for high-sensitive troponin
4. Colchicine in ischemic heart disease: the good, the bad and the ugly
5. Thin-cap fibroatheroma: the trigger of acute coronary syndromes. Pathophysiological and prognostic importance of in-vivo detection
6. 2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
7. Cardiac contractility modulation for patient with refractory heart failure: an updated evidence-based review
8. Editorial: Inflammation in ischemic heart disease: pathophysiology, biomarkers, and therapeutic implications.
9. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
10. Abstract 14661: High Sensitive Troponin Elevation Pattern in Covid-19 Era
11. Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation
12. Feasibility, effectiveness, and safety of edoxaban administration through percutaneous endoscopic gastrostomy: 12-months follow up of the ORIGAMI study
13. 89 GUIDE EXTENSION CATHETER: INDICATION, USE AND RESULTS IN A LARGE SERIES OF COMPLEX PERCUTANEOUS CORONARY INTERVENTIONS
14. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs. without left ventricular unloading by Impella: a systematic review and meta-analysis
15. Multicolor flow cytometry on pericardial effusion for a prompt diagnosis and treatment of hematological malignancies with heart involvement
16. Who, When, and How to Vent During Venoarterial Extracorporeal Membrane Oxygenation?
17. Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?
18. A 3-Year Single Center Experience With Left Atrial Pressure Remote Monitoring: The Long and Winding Road
19. ‘Here comes the story of the Hurricane’: a case report of AL cardiac amyloidosis and myocardial bridging
20. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs without left ventricular unloading by Impella: a systematic review and meta-analysis
21. Who, When, and How to Vent During Venoarterial Extracorporeal Membrane Oxygenation?
22. Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?
23. A 3-Year Single Center Experience With Left Atrial Pressure Remote Monitoring: The Long and Winding Road
24. Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation
25. Advances and Challenges in Biomarkers Use for Coronary Microvascular Dysfunction: From Bench to Clinical Practice
26. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs. without left ventricular unloading by Impella: a systematic review and meta-analysis
27. 2019 novel Coronavirus: current knowledge, cardiovascular implications and management
28. Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective
29. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
30. Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?
31. Stay Home! Stay Safe! First Post-Discharge Cardiologic Evaluation of Low-Risk–Low-BNP Heart Failure Patients in COVID-19 Era
32. Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?
33. A nontrivial differential diagnosis in COVID-19 pandemic: A case report and literary review of amiodarone-induced interstitial pneumonia
34. Colchicine in ischemic heart disease: the good, the bad and the ugly
35. Stay home! stay safe! first post-discharge cardiologic evaluation of low-risk–low-bnp heart failure patients in covid-19 era
36. Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases
37. 2019 novel Coronavirus: current knowledge, cardiovascular implications and management
38. Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration.
39. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
40. Cardiac contractility modulation: a treatment option for patients with refractory heart failure
41. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
42. Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19–Negative Patients?
43. A Nontrivial Differential Diagnosis in COVID-19 Pandemic: A Case Report and Literary Review of amiodarone-induced Interstitial Pneumonia
44. 606 Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the Origami study
45. ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
46. Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19–Negative Patients?
47. Cardiac contractility modulation for patient with refractory heart failure: an updated evidence-based review
48. 2019 novel coronavirus: what is currently known, cardiovascular implications and management
49. Free light chains a novel biomarker of cardiovascular disease. A pilot study
50. Colchicine in ischemic heart disease: the good, the bad and the ugly.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.